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Mutations causing low level 
antibiotic resistance ensure 
bacterial survival in antibiotic-
treated hosts
Jakob Frimodt-Møller1,4, Elio Rossi  2, Janus Anders Juul Haagensen1, Marilena Falcone  2, 
Søren Molin1 & Helle Krogh Johansen  2,3
In 474 genome sequenced Pseudomonas aeruginosa isolates from 34 cystic fibrosis (CF) patients, 
40% of these harbor mutations in the mexZ gene encoding a negative regulator of the MexXY-OprM 
efflux pump associated with aminoglycoside and fluoroquinolone resistance. Surprisingly, resistance 
to aminoglycosides and fluoroquinolones of mexZ mutants was far below the breakpoint of clinical 
resistance. However, the fitness increase of the mutant bacteria in presence of the relevant antibiotics, 
as demonstrated in competition experiments between mutant and ancestor bacteria, showed that 1) 
very small phenotypic changes cause significant fitness increase with severe adaptive consequences, 
and 2) standardized phenotypic tests fail to detect such low-level variations. The frequent appearance 
of P. aeruginosa mexZ mutants in CF patients is directly connected to the intense use of the target 
antibiotics, and low-level antibiotic resistance, if left unnoticed, can result in accumulation of additional 
genetic changes leading to high-level resistance.
Pseudomonas aeruginosa is a frequent colonizer of the airways of cystic fibrosis (CF) patients, where it adapts 
easily and readily establishes chronic infections1,2. Treatment of P. aeruginosa lung infections is usually based on 
susceptibility testing of clinical isolates cultured from the patients’ airways secretions. In the initial period of col-
onization the aim is complete eradication of the infecting bacteria (P. aeruginosa) whereas in later stages the aim is 
at improving the lung function and diminish lung tissue damage, inflammation and thereby loss of lung function. 
However, the clinical outcome often does not confirm the importance of the intensive and frequent antibiotic 
treatment strategy, since in many cases the targeted bacteria persist in the patient airways despite their suscepti-
bility to the administered drug3. For example, no correlation between antibiotic susceptibility to tobramycin and 
ceftazidime and clinical outcome has been reported4. A large number of P. aeruginosa isolates (n = 474) obtained 
from 34 young CF patients were genotyped by whole genome sequencing, and it was found that a small number 
of genes (n = 52) were targeted by patho-adaptive mutations, suggested to increase P. aeruginosa fitness during 
adaptation in the CF lungs5. Among these mutations, it was found that mutations in the mexZ gene were more 
frequent than any other patho-adaptive mutation in agreement with findings from other studies6–11.
MexZ is a negative regulator of the mexXY genes12, which together with oprM encode the MexXY-OprM efflux 
pump13. MexXY-OprM is one of four multidrug efflux systems of the resistance-nodulation-cell division family 
in P. aeruginosa14. The MexXY-OprM pump is often associated with active efflux of aminoglycosides and fluoro-
quinolones15, and recently aminoglycoside resistance in P. aeruginosa isolated from CF patients was reported to 
arise from convergent evolution in the mexZ gene16.
In many CF centers inhalation of tobramycin with or without per oral ciprofloxacin is one of the most impor-
tant antibiotic therapies against initial and subsequent P. aeruginosa airway infections17. Moreover, tobramycin 
is one of the most frequently used drugs for intravenous (i.v.) treatment of chronically infected CF patients, and 
oral ciprofloxacin is used for maintenance therapy between i.v. courses to diminish inflammation and loss of lung 
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function18. Because of the frequent use of aminoglycosides and fluoroquinolones in CF therapy there is a major 
selection pressure for increased tolerance to these antibiotics, arguably including constitutive overproduction of 
mexXY in P. aeruginosa during adaptation to the CF airways. Mutations in the genes PA5471.1, armZ, mexZ, and 
in the genes encoding the two-component system ParRS, have all been described to result in overproduction of 
mexXY15.
This study was initiated on the basis of (1) genomic investigations of 474 P. aeruginosa isolates from CF 
patients5, which showed that mutations in mexZ were more frequent that changes in any other gene; and (2) lack 
of correlation between these mutations and clinically relevant antibiotic resistance. It was therefore considered 
important to determine the phenotype of mexZ mutant strains in order to identify the selection pressure in CF 
airways, which could enrich for the occurrence and maintenance of mexZ bacterial cell lines.
Results
Mutations in mexZ identified in P. aeruginosa from airways of CF patients. Among the 474 
genome sequenced P. aeruginosa isolates5 we identified 193 isolates harboring mutations in the mexZ gene. These 
isolates represent 20 of the 36 clone types isolated from 23 of the 34 CF patients from whom the isolate collec-
tion was obtained5. We identified 110 insertion or deletions (INDELs) and 83 single-nucleotide non-synony-
mous mutations (SNPs) constituting 40 unique sequence variants that were scattered throughout the gene coding 
sequence with no apparent mutational hot-spots (Supplementary Fig. S1 and Table S1). However, we did observe 
a slightly higher number of mutations localized in the C-terminal domain of MexZ in agreement with previ-
ous findings16. Interestingly, 30 of the 40 unique sequence variants were INDELs (Supplementary Fig. S1 and 
Table S1) similar to some of the previously published data7, and in contrast to other studies that have reported 
higher frequencies of SNPs10 (Supplementary Fig. S1). The clinical mexZ mutations in this study either resulted 
in a frameshift or a non-synonymous mutation (Supplementary Fig. S1 and Table S1). All the non-synonymous 
mutations mapped to each of the three domains of MexZ, in the proximity of genomic loci that have been pre-
viously connected with loss of MexZ function19. Thus, we expected that the vast majority of the reported clinical 
mutations in the mexZ gene lead to a complete loss-of-function and an increased expression of mexXY. Moreover, 
no direct association was found between type of mutation (SNP/INDEL), specific mutation locus, and the antibi-
otic resistance phenotype (Fig. 1). None of the 474 sequenced isolates harbored mutations in parR or PA5471.1, 
Figure 1. Mapping of clinical obtained mutations within the mexZ gene in P. aeruginosa. Here, mexZ mutations 
were mapped to one of the three functional mexZ domains; the DNA binding domain (α-helix 1 to α-helix 3), 
where α-helix 3 is the DNA recognition helix, and a C-terminal domain (α-helix 4 to α-helix 9)19. For each 
domain, the number of mexZ mutations consisting of a SNP or INDEL is noted with the accompanying MIC 
determination for the known MexXY-OprM substrates tobramycin, ciprofloxacin, and gentamicin. The clinical 
break-off points are presented according to EUCAST guidelines21.
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while one isolate had a mutation in PA5471, and eight isolates had mutations in parS. Six of the eight isolates con-
taining a parS mutation also had a mexZ mutation. However, we found no correlation between multiple regulator 
mutations and resistance to any of the tested antibiotics. In addition, we found no evidence for mexZ being fixed 
together with any other specific mutations. These observations suggests that among the clinical P. aeruginosa 
isolates from CF patients at the Copenhagen CF Clinic, mexZ is by far the dominant target gene for mutations 
potentially affecting expression of mexXY. The strong selection for mutations in mexZ was further documented by 
fixation of the mutated alleles over time in the airway populations (Supplementary Figs S2 and S3).
The regulatory phenotype of mexZ mutations. To investigate the phenotype of mexZ mutations in the 
clinical P. aeruginosa isolates, levels of MexY mRNA were determined from a number of representative strains 
isolated from 3 different CF patients (Fig. 2). In 8 out of 8 mexZ mutants of 3 different clone types harboring 
either missense mutations or deletions, an induction of the MexY mRNA was observed (more than 20 fold), 
whereas a strain with no mutation in mexZ expressed MexY mRNA at the low level similar to the wild-type. This 
suggests that all the different clinical mexZ mutations (both INDELs and SNPs) resulted in loss of function of the 
MexZ regulator. Interestingly, mexY expression varied greatly between the clinical mexZ mutants (from roughly 
30 to 100 fold induction); we did not, however, find any correlation between high mexY expression and increased 
resistance to MexXY-OprM substrates (Fig. 2 and Supplementary Table S2).
Characterization of the functional consequences of mutations in the mexZ gene in the clinical strains is com-
plicated due to the many other mutations accumulated in the genomes of these strains. Therefore, a PAO1 refer-
ence strain with a complete deletion of the mexZ gene was constructed for thorough phenotypic characterization 
of mexZ null-mutations without interference from other mutations in the genome (see details in Supplementary 
Information). We decided to delete the entire mexZ gene in PAO1 in order to construct a true knock-out variant 
and because we predict that the majority of the clinical INDELs and SNPs in our collection are likely to result in 
a functionally inactive MexZ protein (Fig. 2 and Supplementary Table S2), as observed in other works9–11,16,19.
Expression of the efflux pump operon mexXY in PAO1 wild-type and mexZ mutant bacteria was analyzed 
using qPCR (Fig. 3). Aminoglycosides are known to induce the expression of the mexXY operon20. Although the 
aminoglycoside tobramycin is used more frequently in the clinic to treat P. aeruginosa infections in CF patients 
we chose to use amikacin as a model aminoglycoside antibiotic for two reasons: (1) amikacin gave a stronger phe-
notype in MIC experiments (see next paragraph), and (2) amikacin has previously been used as a model amino-
glycoside for investigations of the MexXY-OprM pump16, therefore making easier to compare our results with 
phenotypes deriving from previously documented mutations. We grew bacteria in LB broth in absence or pres-
ence of sub-MIC concentrations of amikacin and determined gene expression of mexZ and mexXY-oprM operon. 
When PAO1 ΔmexZ was grown without antibiotic, a roughly 20-fold increase in mexY transcription compared 
to the wild-type cells grown under the same conditions was observed (Fig. 3). As expected no mexZ transcripts 
were detected in PAO1 ΔmexZ under both growth conditions. PAO1 grown in the presence of sub-MIC con-
centrations of amikacin showed a 7-fold increase in mexY transcription compared to growth in the absence of 
amikacin (Fig. 3). Thus, as expected, the intrinsic response to aminoglycosides leads to an increased expression 
of mexXY15. PAO1 ΔmexZ grown in the presence of sub-MIC concentrations of amikacin only showed a 2.5-fold 
increase in mexY transcription compared to PAO1 grown under the same conditions (Fig. 3). This suggests that 
deletion of mexZ results in a maximal induction of mexXY (with or without antibiotics), and an overall 2.5-fold 
extra expression in the presence of amikacin. Interestingly, the OprM transcription level was unaltered in PAO1 
ΔmexZ grown with or without the addition of amikacin (Fig. 3). These qPCR data confirm that inactivation of 
mexZ gene results in mexXY induction during growth.
To fully understand the consequences of mutations in the mexZ regulatory gene, we investigated global gene 
expression profiles of PAO1 wild type and mexZ mutant by genome-wide RNA sequencing. Cells were grown 
in LB without antibiotics, and RNA was extracted at OD600 0.5. RNA sequencing showed little or no difference 
between the cellular transcriptomes of PAO1 and PAO1 ΔmexZ. Indeed, only three differentially expressed genes 
Figure 2. MexZ and mexY expression for selected clinical isolates. Relative expression of mexZ and mexY 
determined by RT-qPCR on RNA extracted from selected clinical isolates all of which contained a mexZ 
mutation apart from sample #1 from patient 9 (see Table S3 for details). All data were normalized to 16S RNA 
and ΔCt values between the genes of interest and 16S RNA were set at 1 for PAO1 wild-type strain. Experiments 
were performed in triplicate.
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were identified as a result of the mexZ mutation: mexX and mexY transcription was induced, while mexZ mRNA 
levels were reduced, as expected (Table 1). These results confirm what was observed in qPCR analysis and clearly 
show that the MexZ regulator only affects expression of mexXY operon, without influencing any other transcrip-
tional activities.
Antibiotic resistance levels in mexZ mutant strains. MIC values for the 474 clinical isolates of P. 
aeruginosa including 184 out of 193 mexZ mutants were determined using E-tests (Liofilchem®, Roseto degli 
Abruzzi, Italy) for 8 clinically relevant antibiotics including tobramycin and ciprofloxacin, and susceptibil-
ity/resistance definitions are according to the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) guidelines21 (Table 2). This analysis showed that the mexZ mutation only confers phenotypic resist-
ance to few of the tested antibiotics. For instance, only 12 of the 184 (7%) investigated mexZ mutants were resist-
ant to the MexXY-OprM substrate tobramycin, and 52 showed clinical resistance to ciprofloxacin (Table 2).
The constructed PAO1 ΔmexZ mutant was also analyzed for its resistance to antibiotics using E-tests and 
the broth dilution method (Table 3). The chromosomal deletion of mexZ in PAO1 only affected the MIC of 
the already known MexXY-OprM substrates fluoroquinolones and aminoglycosides. Deleting mexZ in PAO1 
resulted in slightly increased MIC values for all tested aminoglycosides as well as for ciprofloxacin. These slightly 
increased resistance levels were caused by induction of the MexXY-OprM pump, since cultures of PAO1 ΔmexY 
showed a decreased MIC value for the same compounds compared to the wild-type (Table 3). Increasing the 
OprM concentration in PAO1 ΔmexZ, using pXZL34 with an IPTG inducible OprM construct22, did not increase 
resistance to ciprofloxacin or amikacin (data not shown), suggesting that although OprM is expressed from the 
distal MexAB-OprM operon and is also required for the function of the MexAB efflux pump, the OprM level is 
not limiting for efflux pump activity when MexXY is fully induced and is sufficient to support the function of 
both the MexAB-OprM and the MexXY-OprM efflux pump. The differences in MIC between the mutants and 
their wild-type ancestor, PAO1, were in all cases minor, and none of the increased MIC values for PAO1 ΔmexZ 
could be categorized as ‘resistance’ based on the EUCAST break-off points for amikacin, tobramycin, gentamicin 
Figure 3. mexY and oprM expression. Comparative expression of the MexZ, MexY and OprM mRNA by RT–
qPCR of PAO1 and PAO1 ΔmexZ, bacteria grown to exponential phase (OD600 = 0.5) in LB medium. Every 
experiment were related to PAO1 (wild-type) as indicated by the dash line. If amikacin was supplemented it was 
added at OD600 0.1 at sub-MIC concentration (1 µg/mL). All data were normalized to the endogenous reference 
gene rpsL15. No mexZ expression was detected in experiments with PAO1 ΔmexZ and no bar is shown. 
Experiments were performed in triplicate.
Gene Function Log2 (fold change)
PAO1 ΔmexZ
mexZ Transcriptional regulator −2.11
mexX Periplasmic efflux lipoprotein +2.07
mexY Efflux protein +2.20
Table 1. Transcriptomic profiling of mexZ mutant strains. Cultures of PAO1 and PAO1 ΔmexZ, were grown 
to exponential phase (OD600 = 0.5) in LB medium. For each strain, total RNA was extracted from at least three 
independent biological replicates. Genes preferentially expressed in the wild-type ancestor compared to their 
respective ΔmexZ mutants are indicated by negative log2 fold changes and genes preferentially expressed in 
ΔmexZ mutants compared to their respective wild-type ancestor are indicated by positive log2 fold changes.
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or ciprofloxacin21. When referring to MIC values in the following experiments we are referring to MIC values 
obtained only using the broth dilution method. The MIC determinations of the PAO1 ΔmexZ mutant are in 
agreement with the MIC data obtained from P. aeruginosa isolated from CF patients; i.e., there is no consistent 
correlation between a mutation in the mexZ gene and the clinical resistance to MexXY-OprM substrates. This 
may indicate that the in-patient selection pressure for mexZ mutations in P. aeruginosa may be driven by other 
factors than antibiotics.
Several environmental stress factors have been reported to interfere with the bacterial persistence in 
the airways of CF patients: increased levels of reactive oxygen species (ROS)23, bile aspiration caused by 
gastro-esophageal reflux24, and an abnormally increased Cl- concentration25. ROS have been reported to induce 
mexXY expression in a PA5471 dependent fashion26. We therefore investigated whether a mexZ mutant exhibits 
an advantage over the wild-type if challenged by any of these stress factors. However, sensitivities to ROS, bile 
salt, and NaCl were equal for wild-type and mexZ mutants in all tested isolates, and none of these factors therefore 
Tobramycin Sensitive [4≤] Resistance [>4]
Res phenotype INDEL in mexZ n = 104 101 (97%) 3 (3%)
SNP in mexZ n = 80 71 (89%) 9 (11%)
TOTAL n = 184 172 (93%) 12 (7%)
Fraction of TOB resistance strains with a mexZ mutation: 12/30 (40%)
Ciprofloxacin Sensitive [0.5≤] Intermediate [0.75–1] Resistance [>1]
Res phenotype INDEL in mexZ n = 104 40 (38%) 33 (32%) 31 (30%)
SNP in mexZ n = 80 47 (59%) 12 (15%) 21 (26%)
TOTAL n = 184 87 (47%) 45 (25%) 52 (28%)
Fraction of CIP resistance strains with a mexZ mutation: 45/75 (60%) 52/107 (49%)
Gentamicin Sensitive [4≤] Resistance [>4]
Res phenotype INDEL in mexZ n = 104 83 (80%) 21 (20%)
SNP in mexZ n = 80 56 (70%) 24 (30%)
TOTAL n = 184 139 (76%) 45 (24%)
Fraction of GEN resistance strains with a mexZ mutation: 45/87 (52%)
Colistin Sensitive [4≤] Resistance [>4]
Res phenotype INDEL in mexZ n = 104 104 (100%) 0 (0%)
SNP in mexZ n = 80 80 (100%) 0 (0%)
TOTAL n = 184 184 (100%) 0 (0%)
Fraction of COL resistance strains with a mexZ mutation: 0/0 (0%)
Piperacillin Sensitive [16≤] Resistance [>16]
Res phenotype INDEL in mexZ n = 104 90 (87%) 14 (13%)
SNP in mexZ n = 80 50 (62%) 30 (38%)
TOTAL n = 184 140 (76%) 44 (24%)
Fraction of PIP resistance strains with a mexZ mutation: 44/90 (49%)
Aztreonam Sensitive [1≤] Intermediate [1.5–16] Resistance [>16]
Res phenotype INDEL in mexZ n = 104 32 (30%) 64 (62%) 8 (8%)
SNP in mexZ n = 80 18 (23%) 44 (54%) 18 (23%)
TOTAL n = 184 50 (27%) 108 (59%) 26 (14%)
Fraction of AZT resistance strains with a mexZ mutation: 108/363 (30%) 26/46 (57%)
Ceftazidime Sensitive [8≤] Resistance [>8]
Res phenotype INDEL in mexZ n = 104 95 (91%) 9 (9%)
SNP in mexZ n = 80 64 (80%) 16 (20%)
TOTAL n = 184 159 (86%) 25 (14%)
Fraction of CEF resistance strains with a mexZ mutation: 25/65 (38%)
Meropenem Sensitive [2≤] Intermediate [2.5–8] Resistance [>8]
Res phenotype INDEL in mexZ n = 104 84 (80%) 11 (11%) 9 (9%)
SNP in mexZ n = 80 61 (76%) 10 (13%) 9 (11%)
TOTAL n = 184 146 (79%) 21 (12%) 18 (9%)
Fraction of MER resistance strains with a mexZ mutation: 21/44 (47%) 18/51 (35%)
Table 2. MIC determination for clinical P. aeruginosa isolates mexZ mutations. MIC determined with E-tests 
(Liofilchem®, Roseto degli Abruzzi, Italy) on Müller-Hinton agar; Amikacin (AMK), Tobramycin (TOB), 
Gentamicin (GEN), Ceftazidime (CEF), Meropenem (MER), Aztreonam (AZT), Ciprofloxacin (CIP), and 
Colistin (COL). MIC determinations for each antibiotic are given for the total population of mexZ mutants 
as well as the fraction of mexZ mutants with either an insertions/deletions (INDEL) or a Single-Nucleotide 
Polymorphism (SNP). In addition, the fraction of resistant strains with a mexZ mutation is given for each tested 
antibiotic. MIC values were compared to the clinical EUCAST breakoff points21.
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seem to explain the positive selection for the mexZ mutation in vivo (Table 3)26. Furthermore, no difference was 
observed between the wild-type and ΔmexZ when grown in presence of multiple stresses: 0.5 X MIC ROS, 0.5 
X MIC amikacin, and 0.5 X MIC NaCl (data not shown). When the concentrations of ROS, amikacin, and NaCl 
were increased no bacteria survived, as expected. Thus, no apparent differences in the ability to survive CF airway 
stress were observed when comparing wild-type and mexZ mutant bacteria.
Growth physiology and catabolic properties of mexZ mutants. The apparent selective advantage of 
mexZ mutations could be the result of increased growth rates, improved capacities to utilize one or more carbon 
sources, or to form biofilm in sputum. Doubling times were determined both in LB and in ASM, which mimics 
the nutrient composition in CF lungs27. No significant growth rate differences were observed when comparing 
mexZ mutant and wild-type isolates, and biofilm development analyzed under two different growth conditions, 
LB and 1 X M9 minimal media with 0.2% glucose, also showed no measurable difference (Table 3).
We used the Omnilog Biolog (Biolog, Hayward CA, USA) system to monitor the catabolism of 190 differ-
ent carbon sources for PAO1 and PAO1 ΔmexZ (Supplementary Fig. S4A,B). PAO1 and PAO1 ΔmexZ were 
able to catabolize the same carbon sources and we found no significant differences in growth when using these 
(Supplementary Fig. S4A,B).
Fitness increase of mexZ mutant cells in presence of antibiotics. In order to assess the importance 
of the only phenotypic change observed for the mexZ mutant relative to its wild type ancestor, i.e. the very small 
increases in aminoglycoside and fluoroquinolone resistance, the growth and fitness properties of the two PAO1 
strains in presence of sub-lethal concentrations of antibiotics were determined.
First, we investigated whether mexZ deficient cells could have an advantage when growing in medium 
with relevant antibiotics at, or close to, the MIC breakpoint. In presence of sub-MIC concentrations of the 
non-MexXY-OprM substrate, colistin, all strains (PAO1, PAO1 ΔmexZ, and PAO1 ΔmexY) showed identical 
growth phenotypes (Fig. 4A). However, when grown in medium with amikacin or ciprofloxacin (Fig. 4B,C) mexZ 
deficient cells showed a growth phenotype similar to wild-type cells grown without antibiotics, suggesting that in 
these conditions the mexZ mutant has a fitness increase over the wild type strain. This specific growth phenotype 
depends on a functional efflux-pump, since PAO1 ΔmexY shows a reduced growth rate compared to that of the 
wild-type and PAO1 ΔmexZ in media with amikacin or ciprofloxacin (Fig. 4B,C).
AB MIC (µg/mL) E-testa PAO1 PAO1 ΔmexZ PAO1 ΔmexY
AMK 3 6 1
TOB 0.38 0.5 0.125
GEN 1.5 2 0.25
CEF 1.5 1.5 1.5
MER 0.5 0.5 0.5
AZT 3 3 3
CIP 0.064 0.19 0.047
COL 2 2 2
AB MIC (µg/mL) BDb
AMK 1 2 0.5
TOB 1 1 0.5
CIP 0.125 0.25 N/A
COL 2 2 N/A
ES MICc
H2O2 (mM) 0.16 0.16 N/A
Bile salt (%) 0.15 0.15 N/A
NaCl (mM) 0.5 0.5 N/A
Doubling time (min)d
LB 55 54 55
ASM 54 55 N/A
Biofilme
LB 1.04 1.68 N/A
1 X M9 w. 0.2% GLU 0.91 0.96 N/A
Table 3. Wild-type and ΔmexZ phenotype(s). aMIC determined with E-tests on Müller-Hinton agar. Amikacin 
(AMK), Tobramycin (TOB), Gentamicin (GEN), Ceftazidime (CEF), Meropenem (MER), Aztreonam (AZT), 
Ciprofloxacin (CIP), Colistin (COL). bMIC determined using broth dilutions34. Antibiotic abbreviations are 
the same as above. cEnvironmental stress MIC determined using broth dilutions34. dDoubling time calculated 
from growth in LB, artificial sputum medium (ASM) or 1 X M9 w. 0.2% glucose. Cells were grown at 37 °C for 
24 hours shaking. eBiofilm measured by crystal violet staining on cells grown in either LB or 1 X M9 w. 0.2% 
glucose for 24 h in 96-well microtiter plates at 37 °C (no shaking).
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Second, we investigated PAO1 and PAO1 ΔmexZ in a flow-cell biofilm system developed for pharmaco-kinetic 
and -dynamic investigations with dosing of antibiotics according to the treatment regimes of CF patients in the 
clinic. Because ciprofloxacin is primarily used as maintainance therapy between i.v. courses in the clinic18, i.e. 
used as frequently as aminoglycosides if not even more (Supplementary Fig. S2), it was selected to illustrate a 
MexXY-OprM substrate (and meropenem as a non-substrate for same pump) in the flow-cell biofilm system. 
Each of the two strains (tagged with yellow fluorescent protein (YFP) and cyan fluorescent protein (CFP), respec-
tively) were allowed to establish biofilms for 3–4 days in the flow cells before antibiotics were administered (see 
Material and Methods for details). After treatment with antibiotics for 24 hours the biofilms were stained with 
‘dead’ stain propidium iodide (PI) and analyzed in the confocal microscope (Fig. 5A). The individual biomasses 
and dead-cell populations were determined by the quantitative COMSTAT analysis (Fig. 5B). Figure 5 clearly 
shows that the mexZ mutant bacteria signifincantly better (t-test (two-tailed); p-value < 0.001) tolerate the bolus 
of ciprofloxacin than the wild-type bacteria. This is particularly interesting because the mexZ mutant survives, 
even though concentrations of ciprofloxacin above MIC were administered to the biofilm cultures, and despite 
the very moderate difference in MIC between PAO1 and PAO1 ΔmexZ. In a parallel biofilm experiment, in which 
meropenem (not excreted by the MexXY-OprM efflux pump) was administered to the two bacterial populations, 
no difference in survival of the bacteria was observed (Fig. 5). These results show that mexZ mutant bacteria sur-
vive better in clinically relevant antibiotic containing environments, resulting (1) in their competitive advantage 
in populations comprising both wild type and MexZ mutant bacteria, and (2) fixation of the specific mutation.
Next, we tested the mexZ associated fitness increase in competition experiments including equal numbers of 
wild type and mexZ mutant bacteria (tagged differentially with fluorescent proteins) in liquid cultures in shaking 
flasks with low concentrations of antibiotics. In presence of amikacin or ciprofloxacin (sub-MIC concentrations) 
growing for more than 40 generations in direct competition, the mexZ mutant bacteria eventually out-competed 
the wild-type bacteria (Fig. 4F,G). When grown in LB or in LB supplemented with sub-MIC concentrations of 
colistin (which is not excreted by the MexXY-OprM efflux pump), both strains were stably maintained at the same 
ratio (Fig. 4D,E). These results show that mexZ mutations confer increased fitness in environments containing 
relevant antibiotics, and that in absence of these antibiotics mutant and wildtype cells are equally fit.
Discussion
Treating patients suffering from persistent bacterial infections with antibiotics relies to a great extent on careful 
monitoring of resistance development. In line with this need, standardized protocols for clinical antibiotic sus-
ceptibility testing have been developed together with approved values for resistance break points (EUCAST). The 
obvious goal of course is to treat health threatening infections with antibiotics, which are assumed to be effective, 
and to avoid resistance development as much as possible. Previous studies have, however, shown a lack of corre-
lation between clinical antibiotic susceptibility testing and clinical outcome3,4. The striking finding of this study is 
that very small increases in antibiotic resistance associated with mexZ mutations, which normally are undetected 
or neglected in the clinical microbiological laboratory using current standardized diagnostic methods, seem to 
be drivers of selection of mexZ mutants in CF patients. When P. aeruginosa colonizes the CF airways the bacteria 
are challenged with different stress factors, which may interfere with persistence, such as presence of antibiotics, 
increased levels of ROS23, bile aspiration caused by gastro-oesophageal reflux24, and an abnormally increased Cl− 
concentration25. Surprisingly, however, we did not observe any marked difference in susceptibility to any of these 
stress factors, when comparing wild type and mexZ mutant under standard laboratory conditions. In addition, 
the mexZ mutants did not show any change in growth rate nor improved potential to form biofilm. However, 
when MexZ deficient bacteria were competed against wild type bacteria in presence of sub-MIC concentrations 
of amikacin or ciprofloxacin, the mutant bacteria quickly outcompeted the wild type. This was true both in direct 
competition in LB Broth (Fig. 4), and in our flow-chamber biofilm system, which mimics the P. aeruginosa bio-
film lifestyle and the antibiotic treatment used in the CF clinic28, the mutant bacteria survived better than the 
wildtype bacteria (Fig. 5A,B). These results show that mexZ deficient bacteria are superior to the wild-type strains 
in clinically relevant sub-MIC growth conditions, which most likely are found in the lungs and sputum of CF 
patients during antibiotic treatment.
Since aminoglycosides and fluoroquinolones are very important first-line drugs for treating P. aeruginosa 
airway infections in CF patients, it is of major importance that changes in antibiotic susceptibility are identified 
in the clinical microbiological laboratory. However, the differences in aminoglycoside and fluoroquinolone MIC 
values for the mexZ mutant relative to those of the wild-type ancestor, PAO1, were in all cases minor, and none of 
the increased MIC values for PAO1 ΔmexZ could be categorized as resistance based on the EUCAST break-off 
points for amikacin, tobramycin, gentamicin or ciprofloxacin21. The discrepancy between the accumulation of 
mexZ mutations, and the lack of a clear antibiotic resistance phenotype when standard EUCAST methods for 
antibiotic resistance assessments are used21, creates a clinical problem since the fitness increases of the mutant 
bacteria in presence of the relevant antibiotics remain undetected, and therefore treatment may erroneously be 
continued. In fact, all 13 CF patients listed in Supplementary Fig. S2 received tobramycin and/or ciprofloxacin 
treatment after the fixation of mexZ mutations in the respective P. aeruginosa populations.
Genetic changes increasing even slightly the fitness of an infecting bacterial populations under conditions 
of antibiotic treatment may also increase the chance of acquisition of new mutations making the bacteria 
truly resistant to the respective antibiotics. Recently, an investigation of antibiotic resistance development in 
Mycobacterium smegmatis documented how mutations in genes encoding ribosomal components, resulting in 
low-level resistance to one or more antibiotics, may promote the subsequent acquisition of mutations resulting 
in high-level antibiotic resistance29. We suggest that mexZ mutations in a similar but mechanistically different 
way, may create evolutionary opportunities for the mutant subpopulations to evolve high-level resistance (cf. 
Supplementary Fig. S3; Patient 1). In addition, we also observed clonal interferences between competing line-
ages with different beneficial mexZ mutations (cf. Supplementary Fig. S2; Patient 5). Here, three different mexZ 
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Figure 4. mexZ deficient bacteria has a faster recovery rate when challenged with MexXY-OprM substrates. In 
panel (A–C) we see antibiotic tolerance measured over time for PAO1, PAO1 ΔmexZ, and PAO1 ΔmexY to; 
(A) sub-MIC concentrations of colistin (1 µg/mL), (B) sub-MIC concentrations of ciprofloxacin (0.064 µg/mL), 
and (C) sub-MIC concentrations of amikacin (0.5 µg/mL). In (A,B), and (C) PAO1 was grown in the absence of 
colistin, amikacin, or ciprofloxacin, serving as a control. Panel (D) to (G) shows direct competition experiments 
between PAO1 Tn7:gfp (PAO1) and PAO1 ΔmexZ; (D) competition in LB in the absence of antibiotic, 
(E) competition in LB supplemented with sub-MIC concentrations of colistin (1 µg/mL), (F) competition 
in LB supplemented with sub-MIC concentrations of ciprofloxacin (0.125 µg/mL), (G) competition in LB 
supplemented with sub-MIC concentrations of amikacin (1 µg/mL). Bars represent the standard error of the 
log10 mean number of CFU per ml.
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mutations approached fixation simultaneously, with one of them eventually being the sole mexZ mutation isolated 
from this patient for the entire study period.
Although our mexZ investigation is relevant for the chronic bacterial persistence in the upper airways in CF 
patients, the basic idea that beneficial mutations can evade clinical microbial diagnostics can be extrapolated to 
other genes in unrelated infection scenarios. It is imperative for optimal and effective antibiotic treatments of 
chronic bacterial infections that the diagnostic determination of antibiotic susceptibility is correct and consti-
tutes a reliable information base for designing a treatment strategy for the patient. If the clinical microbiology 
laboratory only determines antibiotic susceptibility of bacteria according to the standardized guidelines, it is 
highly likely that relevant mutations conferring phenotypic low-level antibiotic resistance will be ignored, which 
may have important consequences for the efficacy of the treatment, as reported here for the mexZ mutations in 
P. aeruginosa. Although the treatment strategies have improved significantly during the last decades, resulting 
in prolongation of the life span of CF patients17, there is room for further development of even more effective 
antibiotic regimens delaying the chronic infection state of the most problematic bacterial infections such as those 
caused by P. aeruginosa30. For CF patients based on the discordance between the clinical antibiotics susceptibility 
Figure 5. Survival of PAO1 wild-type and PAO1 ΔmexZ during treatment of biofilms with ciprofloxacin and 
meropenem. (A) Representative images of PAO1 tagged with yellow fluorescent protein and PAO1 ΔmexZ 
tagged with cyan fluorescent protein after live/dead staining (dead cells were stained for visualization using 
propidium iodide). Biofilms were either untreated, treated with one bolus (4 mg/l) Ciprofloxacin treatment 
for 24 h, or one bolus (107 mg/l) Meropenem for 24 h. Biofilms were grown on glucose minimal medium and 
treated with antibioitcs at day 3 (see Material and Methods). (B) COMSTAT quantification of the biomass of 
live and dead cells after live/dead staining of a PAO1 wild-type biofilm and PAO1 ΔmexZ biofilm from the same 
treatment regime as described in (A). In at least two independent experiments 3–4 random images were taken 
from each flow channel. A t-test (two-tailed) was performed between PAO1 and PAO1 ΔmexZ treated with 
ciprofloxacin showing a highly significant difference in survival (p < 0.001) as indicated by the three ***.
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test results and the clinical outcomes, we suggest that targeted genotypic investigations may positively comple-
ment routine susceptibility testing, informing about genetic changes, which may have predictive impacts on the 
non-detectable resistance profile and associated persistence of colonization of the airway population.
Material and Methods
Growth conditions. Clinical isolates of P. aeruginosa were grown in Lysogeny Broth (LB) medium, 1 X M9 
minimal medium supplemented with 0.2% glucose, or in artificial sputum medium (ASM)27. All liquid cultures 
were incubated at 37 °C with shaking (200 r.p.m.) unless otherwise stated. Escherichia coli was cultured on LB agar, 
and P. aeruginosa was cultured on Pseudomonas Isolation Agar (PIA; Sigma-Aldrich Co. LLC., St. Louis, USA) 
or LB agar. When necessary, antibiotics were added to the following concentrations: gentamicin, 100 µg/ml for 
P. aeruginosa and 10 µg/ml for E. coli; chloramphenicol, 20 µg/ml; ampicillin, 150 µg/ml; kanamycin, 50 µg/ml.
Bacterial strains and plasmids. All strain and plasmid constructs are listed in Supplementary Materials 
and methods and in Supplementary Table 1. Oligonucleotides for PCR are listed in Supplementary Table 2. In 
addition, we used a collection of 474 genome sequenced P. aeruginosa isolates from 34 CF children and young 
adults to measure the minimal inhibition concentration (MIC), using relevant antibiotics, for clinical strains 
with- and without a mexZ mutation.
Total RNA isolation. For RNA-seq and quantitative real-time-PCR (qRT-PCR) experiments, cultures were 
grown to exponential phase (OD600 = 0.5) in LB medium. For each strain, total RNA was extracted from at 
least three independent biological replicates using Trizol reagent (Thermo Fisher Scientific Inc.) followed by 
RNA clean & concentrator kit (Zymo Research, Irvin, USA) accordingly to vendors’ protocols. RNA quality was 
checked using RNA Nano kit on an Agilent Bioanalyzer 2100 machine. Samples with an RNA integrity number 
(RIN) greater than 9 were used in downstream analysis.
qRT-PCR. For qRT-PCR experiments, after genomic DNA digestion, 1 µg of total RNA was retrotranscribed 
using QuantiTect Reverse Transcription kit (Qiagen, Venlo, Netherlands). Primers designed to amplify mexZ, 
mexY, and oprM (Supplementary Table 2) were targeted to regions of unique sequences within the genes in 
wild-type PAO1. The qRT-PCR was performed using the QuantiTect SYBR® Green PCR Kit (Qiagen, Venlo, 
Netherlands) on an Agilent Stratagene Mx3000P qPCR system. All data were normalized to either the 16S RNA 
(Fig. 2) or the endogenous reference gene rpsL15 (Fig. 3). These data were transformed to log2 to obtain a change 
difference (n-fold) between strains.
RNA sequencing and data analysis. For RNA-sequencing experiments, 10 µg of total RNA was depleted 
of ribosomal RNA using Ribo Zero rRNA removal kit for Gram-negative bacteria (Illumina). Strand-specific 
sequencing libraries were prepared using 50 ng of mRNA-enriched samples as input for TruSeq stranded mRNA 
library preparation kit (Illumina) following vendor’s recommendations. Sequencing was performed on an 
Illumina NextSeq 500 system to a depth of 15–20 million reads per samples. After quality filtering, raw reads 
were aligned using BWA aligner against the relevant genome (P. aeruginosa PAO1: NC_002516.2). Read counts 
for gene relative abundance were obtained using HTSeq-count tool from HTSeq package31,while gene differen-
tial expression and statistical analysis were performed as previously described32. The transcriptomic data have 
been submitted to the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/) and assigned the identifier 
E-MTAB-5820.
Optical density measurements over time. The stress resistance assay was performed as previously 
described33. In short, the overnight cultures were diluted to a final desired inoculum of 5 × 105 cfu/mL, as 
described by Wiegand et al.34, with and without the antibiotic, and growth was monitored at OD600 in 96-well 
microtitre polystyrene plates for 20–24 h. The concentration of the antibiotic was adjusted to avoid killing of the 
bacteria; i.e. no visible growth after 24 hours. Here we used amikacin (0.5 µg/mL), ciprofloxacin (0.064 µg/mL), 
and colistin (1 µg/mL).
Minimal inhibition concentration measurements (MIC). E-test. E-tests were performed with 
Mueller-Hinton agar plates (diameter, 140 mm) as previously described35. The direct colony suspension method 
was used to make a suspension of PAO1, PAO1 ΔmexZ and PAO1 in saline to the density of McFarland 0.5 
turbidity standard, approximately corresponding to 1–2 × 108 CFU/mL for E. coli. E-tests (Liofilchem®, Roseto 
degli Abruzzi, Italy) for clinical relevant antibiotics were used; amikacin, tobramycin, gentamicin, ciprofloxacin, 
colistin, ceftazime, meropenem, and aztreonam. After application of the E-test, the plates were incubated at 37 °C 
for 16–20 h. MIC values were compared to the clinical EUCAST breakoff points21.
Broth micro-dilution. Broth micro-dilutions were performed in 96-well microtiter plates (polystyrene plates 
(BD Falcon; Fisher Scientific, cat. no. 351177)) as previously described with the exception that dilutions were 
performed in LB broth, not in Mueller-Hinton broth. Broth micro-dilutions were done for the clinically relevant 
antibiotics (all from Sigma-Aldrich Co. LLC.) amikacin, tobramycin, ciprofloxacin, and colistin. In addition, the 
MICs with respect to hydrogen peroxide (Thermo Fisher Scientific Inc.), NaCl (Thermo Fisher Scientific Inc.), 
and bile salts (Oxgall; Neogen Corporation, Lansing, USA) were tested using the same protocol. After addition 
of antibiotic or stress factor, plates were incubated at 37 °C for 16–20 h. The MIC was defined as the lowest con-
centration of the antimicrobial agent or stress factor that inhibits visible growth of the tested isolate as observed 
with the unaided eye34.
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Biolog Phenotype Microarrays. Biolog Phenotype Microarrays were performed as previously described36. 
In short, PAO1 and PAO1 ΔmexZ strains were streaked on LB agar plates and incubated at 37 °C. Cells were 
swabbed from the plates and suspended in IF-0 GN Base (inoculation fluid) at a density corresponding to 42% 
transmittance in the Biolog turbidimeter. The cell suspensions were diluted in IF-0 minimal medium containing 
Biolog redox dye mixture D (tetrazolium), and aliquots were added to the two different carbon-source plates; 
PM1 and PM2A. The plates were incubated at 37 °C in an OmniLog plate reader (Biolog) for 48 h, and growth/
respiration was measured kinetically by determining the colorimetric reduction of the tetrazolium dye. Export of 
OmniLog data was performed using OmniLog OL_FM/Kin 1.20.02 software (Biolog). The average area beneath 
each kinetic curve was used for analysis. Total catabolic function was calculated as previously described37.
Static biofilms. Biofilm formation in micro-titre plates was analysed as previously described38. PAO1 and 
PAO1 ΔmexZ were grown in either LB or 1 X M9 with 0.2% glucose overnight at 37 °C and diluted into identical 
media for the study of biofilm formation. The biofilm was stained by 0.1% solution of crystal violet (Thermo 
Fisher Scientific Inc.) and quantified in a plate reader (OD550 nm) using the growth media without added bac-
teria as the blank.
Pharmacodynamic/pharmacokinetic (PD/PK) flow chamber biofilms. The PD/PK system is based 
on bacterial biofilms grown under continuous culture conditions, simulating the changing antibiotic concen-
trations in CF patients during i.v. dosing. In this system the antibiotics decay similarly to what takes place in CF 
patients during treatment. Antibiotic treatment of biofilms were performed using differentially tagged strains, 
i.e. PAO1 tagged with yellow fluorescent protein (YFP) and PAO1 ΔmexZ tagged with cyan fluorescent protein 
(CFP). Dead cells were stained for visualization using propidium iodide (see Supplementary Material and meth-
ods for strain constructions). The one-compartment dynamic biofilm PD model has been previously described28. 
Briefly, biofilms were grown at 30 °C in flow chambers for 96 hours, at which point ciprofloxcacin or meropenem 
concentrations modeling human PK were applied. Each flow chamber was inoculated with 250 μL of overnight 
cultures of PAO1 or PAO1 ΔmexZ respectively diluted to an OD600 of 0.05 and left without flow for one hour. 
After one hour, flow was started with 40x diluted LB or minimal medium supplemented with 0.03 mM glucose 
at a flow rate of 20 ml/h using a peristaltic pump (Watson Marlow 205S). After cultivation for 72 hours, flow was 
stopped and medium was replaced with an antibiotic flask containing relevant concentrations of either ciproflox-
acin or meropenem. Flow was restarted and medium was pumped from the dilution flask through the antibiotic 
flask to the flow chambers at a constant rate calculated to mimic the elimination rate constant of the antibiotic. 
Concentration-time profiles were based on PK parameters of ciprofloxacin and meropenem from healthy people 
and patients with CF39,40.
The target ciprofloxacin peak concentration, based on human population values, was calculated to be 400 mg 
IV = 4 mg/L, and for meropenem it was 107.5 mg/L. Using these target concentrations the model allows for the 
simulation of the human PL profile of the antibiotic while maintaining constant flow rate. Experiments were 
repeated 3 times in biological independent runs, and 3–4 images of each channel were collected from each run 
using a Zeiss LSM 510 meta confocal laser scanning microscope (CLSM) equipped with an argon/krypton laser 
and detectors and filter sets for simultaneous monitoring of CFP (excitation 458 nm, emission 490 nm) and 
YFP (excitaiotn 514 nm, emission 530 nm) for live cells, and propidium iodide, PI (excitation 543 nm, emission 
565 nm) for dead cell staining. Images were obtained using a 40x/1.3 Plan-Neofluar oil objective. Multichannel 
simulated fluorescence projections (SFPs) and sections through the biofilms were generated using Imaris software 
(Bitplane AG, Switzerland). CLSM images were analyzed using COMSTAT41.
Ethics approval. The local ethics committee at the Capital Region of Denmark (Region Hovedstaden) 
approved the use of the stored P. aeruginosa isolates: registration number H-4-2015-FSP. We confirm that all 
methods were performed in accordance with the relevant guidelines and regulations.
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